SCCM Pod-504 CCM: Baricitinib or Tocilizumab for Severe COVID-19
Host Marilyn N. Bulloch, PharmD, BCPS, FCCM, is joined by Joy Peterson, PharmD, BCPS, BCIDP, and Neha Paranjape, MD, MPH, to discuss the Critical Care Medicine article, "Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19,” which delves into the comparative outcomes, mortality rates, and adverse effects of baricitinib and tocilizumab in severe COVID-19 cases.
Published: 3/25/2024
Category: CCM Podcast